What does legendary Australian golfer Greg Norman have to do with Cannabis?
Even Abercrombie & Fitch (NYSE:ANF) is getting in on the cannabis product action.
That’s right, the American retailer with the best abs in the business, has expanded its partnership with Green Growth Brands Inc. (CSE: GGB) (OTCQB: GGBXF) and will trial GGB’s Seventh Sense Botanical Therapy products in 10 Abercrombie & Fitch stores.
The retail giant now carries CBD products in more than 160 A&F stores.
The expansion includes Seventh Sense's CBD-infused body lotions, muscle balms, lip balms and sugar scrubs, and is Green Growth Brands' second major wholesale agreement since the passage of the Agriculture Act of 2018 in December 2018.
"Abercrombie & Fitch understands how to connect with their target-customer, not just in the US but across the globe," said Green Growth Brands CEO, Peter Horvath. "They have incredible brand recognition in our current target markets and beyond, and we are excited at the prospect of building our partnership together."
Abercrombie & Fitch operates in more than 250 locations (includes abercrombie kids) worldwide as of the end of Q1 2019 and for more than 125 years has outfitted innovators, explorers and entrepreneurs.
A move into CBD-related accessories and products reflects the updated attitude of the modern consumer.
It’s not the first time, Green Growth Brands has linked up with unlikely sources.
Legendary Australian golfer, Greg Norman is also in the mix.
S3 Consortium Pty Ltd (CAR No.433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information only. Any advice is general advice only. Neither your personal objectives, financial situation nor needs have been taken into consideration. Accordingly you should consider how appropriate the advice (if any) is to those objectives, financial situation and needs, before acting on the advice.
Conflict of Interest Notice
S3 Consortium Pty Ltd does and seeks to do business with companies featured in its articles. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this article. Investors should consider this article as only a single factor in making any investment decision. The publishers of this article also wish to disclose that they may hold this stock in their portfolios and that any decision to purchase this stock should be done so after the purchaser has made their own inquires as to the validity of any information in this article.
The information contained in this article is current at the finalised date. The information contained in this article is based on sources reasonably considered to be reliable by S3 Consortium Pty Ltd, and available in the public domain. No “insider information” is ever sourced, disclosed or used by S3 Consortium.